Search Results for: CLINICAL TRIALS Its Time to
Articles
Catalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell & Gene Therapy Development May 25, 2023
Catalent recently announced it has expanded the services and capabilities at its facility in Shiga, Japan, to include the storage,...QSAM Biosciences & RLS Announce Clinical & Commercial Supply Agreement for Promising Clinical-Stage Metastatic & Primary Bone Cancer Treatment May 16, 2023
QSAM Biosciences, Inc. and RLS (USA) Inc. recently announced a commercial supply and clinical dose preparation agreement for the therapeutic...QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of Targeting Metastatic Bone Cancer April 5, 2023
QSAM Biosciences Inc. recently announced the opening of enrollment into the second grouping of participants (Cohort 2) after completing Cohort...INFLAMMASOME INHIBITORS - 21st Century Miracle Drugs: Spotlight on Clinical NLRP3 Inflammasome Inhibitors April 3, 2023
Bryan Oronsky, PhD, says traditionally, pharmaceutical development is based on the “magic bullet” concept of “one drug, one target, one disease.” However, with the growing realization that chronic inflammation lies at the center of many, if not all, diseases, it is possible to envision inflammasome inhibitors, which reduce or prevent inflammation, as near-universal treatment panaceas.
EXECUTIVE INTERVIEW - ICON: Transforming Clinical Trials in a Rapidly Shifting Landscape April 3, 2023
Ute Berger, MD, President, Development & Commercialization Solutions at ICON plc, discusses how with the acquisition of PRA in 2021, it has enhanced its value proposition and how it is transforming clinical trials in a rapidly shifting landscape.
Kala Pharmaceuticals Announces Positive Safety Update From Cohort 1 of Phase 2b Clinical Trial March 27, 2023
Kala Pharmaceuticals, Inc. recently announced positive safety data from the first cohort of the CHASE (Corneal Healing After SEcretome therapy)...Catalent & Grünenthal Announce Successful Collaboration to Facilitate Expedited Clinical Development Timelines March 15, 2023
Catalent and Grünenthal recently announced their successful formulation design and clinical-phase manufacturing collaboration for an orally dosed small molecule in...QSAM Biosciences Receives FDA Clearance to Expand Enrollment Criteria in its Phase 1 Study Targeting Metastatic Bone Cancer March 8, 2023
QSAM Biosciences Inc. recently announced US FDA has cleared the Company’s amended clinical trial protocol increasing the maximum age of...Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients With Advanced Solid Tumors March 7, 2023
Indaptus Therapeutics, Inc. recently announced the dosing of the first subject in INDP-D101, the company’s first-in-human, open label, dose escalation...CLINICAL TRIALS - New Technology & the Global COVID Pandemic Drive the Need for More Decentralized Trials March 1, 2023
Suhas Gudihal, MS, MBA, explains how the COVID-19 pandemic has accelerated the ongoing shift to remote clinical trial monitoring, and remote site access and monitoring platforms are now an essential element of the clinical trial process and a vital connection between the sponsor, CRO, and research site.
Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain & Function in Rheumatoid Arthritis February 28, 2023
Incannex Healthcare Limited recently announced it has commenced a Phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug….
QSAM Biosciences Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam Targeting Metastatic Bone Cancer February 28, 2023
QSAM Biosciences Inc. recently announced the completion of enrollment in the first participant grouping (cohort) of its Phase 1 study...Kadimastem Submits IND Application for its Phase 2a Clinical Trial With AstroRx for the Treatment of ALS February 20, 2023
Kadimastem Ltd recently has submitted an Investigational New Drug (IND) application to the US FDA for an approval for a multi-site Phase 2a clinical trial to test its lead neurological….
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial February 14, 2023
Purple Biotech Ltd. recently announced the first patient has been dosed in the randomized part of the open label Phase...Syneos Health & Haystack Health Partner to Accelerate Clinical Trials With AI February 7, 2023
Syneos Health recently announced a strategic partnership with Haystack Health, a Roivant Health portfolio company developing advanced Artificial Intelligence (AI) and...Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients With Advanced Solid Tumors February 7, 2023
Indaptus Therapeutics, Inc. recently announced the addition of Morristown Medical Center, part of the Atlantic Health System, as a new...Purple Biotech Expands Pipeline of First-in-Class Therapeutics With Acquisition of Immunorizon & Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer February 2, 2023
Purple Biotech Ltd. recently announced it has entered into an agreement for the acquisition of Immunorizon Ltd., a private company developing potential multi-specific T and NK cell engager oncology therapies that….
Frontera Therapeutics Doses First Patient in a Clinical Trial of Gene Therapy for the Treatment of Wet AMD February 2, 2023
Frontera Therapeutics recently announced it has dosed the first patient in a clinical trial of its innovative gene therapy product,...Gerresheimer Presents its New Clinical Trial Kit to Accelerate Drug Development February 1, 2023
Gerresheimer presents its new Clinical Trial Kit at Pharmapack in Paris. This kit consists of sterile Gx RTF vials in...SPECIAL FEATURE - Outsourcing Analytical Testing – Timelines, Regulations & Biologics Drive the Sector January 17, 2023
Contributor Cindy H. Dubin interviews leading CDMOs to discuss not just their analytical service offerings, but their strategies for meeting regulatory challenges and ensuring faster project timelines.